Skip to main content
Clinical Trials/NCT04091412
NCT04091412
Unknown
Phase 4

Study of Collateral Circulation and Related Gene Polymorphism in Patients With Symptomatic Intracranial Anterior Circulation Aortic Occlusion

The Second Hospital of Hebei Medical University1 site in 1 country500 target enrollmentMay 5, 2019

Overview

Phase
Phase 4
Intervention
Butylphthalide Soft Capsules
Conditions
Collateral Circulation
Sponsor
The Second Hospital of Hebei Medical University
Enrollment
500
Locations
1
Primary Endpoint
collateral circulation level
Last Updated
6 years ago

Overview

Brief Summary

Intracranial artery stenosis is the leading cause of stroke onset or recurrence in Asian. Multiple studies have shown that anterior circulation is most common in intracranial artery stenosis, especially the middle cerebral artery in patients with symptomatic or asymptomatic ischemic stroke. Based on the clinical experiences, we found that the cerebral collateral development can affect clinical symptoms seriously in patients with large artery stenosis. Compensated blood flow can reach the ischemic area through collateral circulation (including circle of Willis, leptomeningeal collaterals, extracranial to intracranial collaterals, and new angiogenesis) when the blood-supplying artery of the brain is severely stenotic or even occluded, however, considerable differences across individuals exist. Studies have shown statins and butylphthalide can promote collateral circulation. The influencing factors on collateral circulation building have not been completely identified yet, but a recent research found that Naturally occurring variants of Rabep2(Rab GTPase binding effector protein 2)are major determinants of variation in collateral extent and stroke severity in mice. On this basis, clinical trials have been conducted in order to confirm that the Rabep2 gene is associated with individual differences in the collateral circulation.

Summarizing new findings, we suspect whether the difference in the degree of collateral circulation is significant for long-term prognosis in patients with cerebral large arterial occlusion, and whether promoting collateral circulation and new angiogenesis can become a new treatment approach. Hereby, we plan to recruit 500 patients with cerebral large-artery occlusion, collect clinical and Imaging (CTA) information, analyze and investigate if the difference in the degree of collateral circulation can be the independent influencing factor for long-term prognosis. This study will collect blood sample of patients and further examine SNPs of Rabep2, and will then analyze the correlation between Rabep2 and patients with cerebral large-artery occlusion. This project will follow up rolled patients for 1 year, observe if long-term intake of butylphthalide can promote cerebral collateral development.

Registry
clinicaltrials.gov
Start Date
May 5, 2019
End Date
May 1, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

liuxiaoyun

Deputy Director of Neurology Department

The Second Hospital of Hebei Medical University

Eligibility Criteria

Inclusion Criteria

  • Patients with arterial occlusion on unilateral or bilateral intracranial segment of internal carotid artery and/or middle cerebral artery were diagnosed by CTA; 2 complete medical records;

Exclusion Criteria

  • CTA showed no arterial occlusion on unilateral or bilateral intracranial segment of internal carotid artery and/or middle cerebral artery;
  • Follow-up interventional surgery;
  • Death within 30 days of onset;
  • Clinical data incomplete;
  • Loss of follow-up patient.

Arms & Interventions

Long-term administration of Butylphthalide Soft Capsules

In addition to standard secondary preventive drugs, such as atorvastatin calcium tablets, aspirin enteric-coated tablets and/or clopidogrel hydrogen sulphate tablets, patients in this group take Butylphthalide Soft Capsules orally, 0.2g per serving, three times a day for one year.

Intervention: Butylphthalide Soft Capsules

Outcomes

Primary Outcomes

collateral circulation level

Time Frame: 1 hour

Evaluation of collateral circulation level based on CTA

Study Sites (1)

Loading locations...

Similar Trials